Radiation Therapy for Liver Cancer

 

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells. Radiation therapy is used after surgery to help prevent the liver cancer from coming back (recurring) or to help treat symptoms. It can be given internally or externally:

  • Internal radiation therapy (brachytherapy or interstitial radiation therapy) - Tiny pellets (or “seeds”) that contain radioactive materials are injected into your bloodstream and guided to the hepatic artery. Tumor blood vessels are smaller than the blood vessels of healthy tissue. As a result, the seeds get stuck in the small blood cells that feed the tumors; however, they pass right through the larger blood vessels that feed healthy liver tissue. The pellets release their radiation slowly into the tumor without damaging healthy tissue. Brachytherapy lets the doctor use a higher dose of radiation than EBRT. This type of treatment involves a one-time procedure.
  • External beam radiation therapy (EBRT) - Radiation from a high-energy x-ray machine (linear accelerator) outside the body is focused on the cancer cells. EBRT can harm both the cancer cells and nearby healthy tissue. Most people are treated with EBRT for a few minutes 5 days a week for 3 to 5 weeks as an outpatient. This technique is rarely used for liver cancer.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on August 22, 2007 .
Latest Cancer News
Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes

March 9, 2010 — Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.

HPV Vaccine Provides Little Benefit for Older Women

March 9, 2010 — Researchers from Costa Rica have reported that women over the age of 40 are not likely to benefit from vaccination to prevent human papillomavirus (HPV). The details of this study were published in the March 3, 2010 issue of the Journal of the National Cancer Institute.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Arimidex

March 9, 2010 — Among postmenopausal women with early, hormone receptor-positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts the risk of distant cancer recurrence in both node-negative and node-positive patients. These results were published in the Journal of Clinical Oncology.

Select news items provided by Reuters Health